Up-To-Date Stock Report: Impax Laboratories Inc. (NASDAQ:IPXL)

Mar 10, 2017, 00:33
Up-To-Date Stock Report: Impax Laboratories Inc. (NASDAQ:IPXL)

However the company observed 52 week high price on 04/22/16 and witnessed 52 week low price on 03/07/17.

The company reported its EPS on 03/01/2017. WallachBeth Capital downgraded shares of Impax Laboratories from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $30.00 to $18.00 in a research note on Monday, November 14th. RBC Capital Markets reaffirmed a sector perform rating on shares of Impax Laboratories in a research report on Tuesday, January 17th. Currently, the stock has a 1 Year Price Target of $14.29. The analyst recommendations from a month ago are 23 Buy, 1 Overweight, 1 Sell, 4 Hold and 0 Underweight. Impax Laboratories Inc (NASDAQ:IPXL)'s price to sales ratio for trailing twelve month stands at 0.98, whereas its price to book ratio for most recent quarter sits at 1.08.

While trading at volume above than average, Impax Laboratories, Inc. 1,621,498 shares of the stock were exchanged. The stock's market cap is $570.56 million. The company's 50-day moving average is $12.75 and its 200-day moving average is $17.38.

Insider Trades for Impax Laboratories Inc. show that the latest trade was made on 25 Feb 2017 where Nestor (Michael J), the Officer completed a transaction type "Sell" in which 5594 shares were traded at a price of $14.05.

Impax Laboratories Inc (NASDAQ:IPXL) is expected to release the earnings of its current quarter on 5/9/17. The specialty pharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.39 by $0.02.

Impax Laboratories Inc. (NASDAQ:IPXL) is now showing its ROA (Return on Assets) of -24.6%. The analysts offering Earnings Estimates for the company were believing that Impax Laboratories Inc. During the same period in the previous year, the firm posted $0.62 earnings per share. The firm's revenue was down 29.7% on a year-over-year basis.

For this year, Impax Laboratories, Inc. Impax Laboratories Inc. got Downgrade on 1-Mar-17 where investment firm Piper Jaffray Downgrade the stock from Neutral to Underweight. If you are reading this piece on another publication, it was illegally stolen and reposted in violation of United States & global trademark and copyright legislation. The Relative Volume value measured for Impax Laboratories Inc.

A number of hedge funds and other institutional investors have recently bought and sold shares of IPXL. Nisa Investment Advisors LLC now owns 5,800 shares of the specialty pharmaceutical company's stock worth $137,000 after buying an additional 5,000 shares during the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Impax Laboratories by 1.7% in the third quarter. KBC Group NV now owns 5,938 shares of the specialty pharmaceutical company's stock worth $141,000 after buying an additional 4,909 shares during the last quarter. Norges Bank acquired a new stake in Impax Laboratories during the fourth quarter valued at $16,669,000. The stock opened for trading at $8.35 and hit $9.5 on the upside, eventually ending the session at $9.1, with a gain of 8.33% or 0.7 points. 1 Analysts have rated it as strong sell. Catalyst Capital Advisors LLC purchased a new position in Impax Laboratories during the third quarter worth $102,000. During the trading on 03/08/2017, Company's stock ranged from $10.57 to $10.83. The Insider Ownership of the company now is 0.5 percent, and Institutional Ownership is 82.8 percent.